| Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity APT Nguyen, E Tsika, K Kelly, N Levine, X Chen, AB West, S Boularand, ... Proceedings of the National Academy of Sciences 117 (29), 17296-17307, 2020 | 61 | 2020 |
| Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain E Xu, R Boddu, HA Abdelmotilib, A Sokratian, K Kelly, Z Liu, N Bryant, ... Molecular Neurodegeneration 17, 1-19, 2022 | 49 | 2022 |
| The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition K Kelly, S Wang, R Boddu, Z Liu, O Moukha-Chafiq, C Augelli-Szafran, ... Experimental neurology 309, 1-13, 2018 | 46 | 2018 |
| Heterogeneity in α-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia A Sokratian, J Ziaee, K Kelly, A Chang, N Bryant, S Wang, E Xu, JY Li, ... Acta neuropathologica 141, 547-564, 2021 | 29 | 2021 |
| Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of α-synuclein CF Brzozowski, BA Hijaz, V Singh, NZ Gcwensa, K Kelly, ES Boyden, ... Acta Neuropathologica Communications 9, 1-18, 2021 | 21 | 2021 |
| Pharmacodynamic biomarkers for emerging LRRK2 therapeutics K Kelly, AB West Frontiers in Neuroscience 14, 567352, 2020 | 18 | 2020 |
| Exosome markers of LRRK2 kinase inhibition S Wang, K Kelly, JM Brotchie, JB Koprich, AB West npj Parkinson's Disease 6 (1), 32, 2020 | 15 | 2020 |
| Evaluation of current methods to detect cellular leucine-rich repeat kinase 2 (LRRK2) kinase activity B Fernández, VG Chittoor-Vinod, JH Kluss, K Kelly, N Bryant, ... Journal of Parkinson's disease 12 (5), 1423-1447, 2022 | 10 | 2022 |
| Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain K Kelly, A Chang, L Hastings, H Abdelmotilib, AB West Brain research 1759, 147372, 2021 | 10 | 2021 |
| Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration L Hastings, A Sokratian, DJ Apicco, CM Stanhope, L Smith, WD Hirst, ... Brain Communications 4 (2), fcac042, 2022 | 2 | 2022 |
| Pathologic α-Synuclein Species Activate LRRK2 in Pro-Inflammatory Monocyte and Macrophage Responses E Xu, R Boddu, HA Abdelmotilib, K Kelly, A Sokratian, AS Harms, ... bioRxiv, 2020.05. 04.077065, 2020 | 1 | 2020 |
| Predictive Markers of LRRK2 Inhibition in Biofluids S Wang, K Kelly, N Schussler, S Boularand, L Dubois, F Hsieh, ... Available at SSRN 3466981, 2019 | 1 | 2019 |
| BRAIN COMMUNICATIONS AIN COMMUNICATIONS L Hastings, A Sokratian, DJ Apicco, CM Stanhope, L Smith, WD Hirst, ... | | 2022 |
| Pharmacodynamic Markers of LRRK2 Inhibition in Biofluids S Wang, K Kelly, N Schussler, S Boularand, L Dubois, F Hsieh, ... bioRxiv, 2020.01. 28.923557, 2020 | | 2020 |
| Pharmacodynamic Responses and Efficacies Associated with LRRK2 Inhibition KJ Kelly The University of Alabama at Birmingham, 2020 | | 2020 |
| Investigation of Aggregative Properties of the Antimicrobial Peptide LL‐37 by Dynamic Light Scattering (DLS) and Electrophoretic Shift Mobility Assay (EMSA) K Kelly, R Zachary, M Craig The FASEB Journal 29, 564.6, 2015 | | 2015 |
| Impact of Birth Outcomes and Genetic Variation on White Matter Microstructure in Neonates K Kelly, S Jha, R Steiner, J Bullins, K Xia, F Zou, M Ahn, H Zhu, M Styner, ... NEUROPSYCHOPHARMACOLOGY 39, S233-S233, 2014 | | 2014 |
